Adult patients taking Wegovy saw a reduced risk of experiencing a major adverse cardiovascular event within the first three months of treatment, according to a secondary analysis of the drug’s clinical trial data, presented May 12 at the European Congress on Obesity.
Here are three notes from the secondary analysis:
- The “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes” trial results were originally published Nov. 11, 2023, in The New England Journal of Medicine.
The trial enrolled 17,604 adults across 41 countries to evaluate the cardiovascular risk reduction associated with a 2.4-milligram semaglutide injection versus placebo, according to a May 13 news release from Novo Nordisk. - Adults with overweight or obesity and heart disease saw a “significant” risk reduction of heart attack, stroke and death within the first three months of Wegovy treatment, before clinically meaningful body weight changes, the release said.
- Similarly, adults with overweight or obesity and heart disease saw a reduced risk of dying from cardiovascular disease, and being hospitalized or needing urgent medical care for heart failure symptoms within the first six months of Wegovy treatment.
